CClinicalTrials.gg
RecruitingNCT06662162i-SIGHT2Updated Aug 26, 2026

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

An interventional study of i-Lumen AMD in Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD) and Intermediate AMD, sponsored by i-Lumen Scientific AUS PTY LTD. Recruiting at 13 sites in 4 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by i-Lumen Scientific AUS PTY LTD · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.

Participants will:

  • Undergo an initial loading regimen, followed by 7 maintenance over the course of 11 months.
  • Participants will return monthly through Month 14 (3 months post-last treatment) for evaluation and monitoring.
02

Conditions studied

  • Age-Related Macular Degeneration
  • Age-related Macular Degeneration (ARMD)
  • Intermediate AMD
  • Geographic Atrophy Secondary to Age-related Macular Degeneration

Keywords

  • AMD
  • Intermediate AMD
  • Dry AMD
  • Geographic Atrophy
03

In context

Macular Degeneration

1,474 studies on the registry are indexed under Macular Degeneration; 206 are open to participants now.

This study's planned enrollment of 100 is above the median of 51 across 985 interventional studies indexed under Macular Degeneration.

Browse Macular Degeneration studies →

Lead sponsor

This is the only study on the registry with i-Lumen Scientific AUS PTY LTD as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Presence of at least one large druse >125 microns in diameter due to AMD.
  • BCVA letter score of 35 to 70 letters (inclusive) (Snellen equivalent 6/12 to 6/60 [20/40 to 20/200])

Key Exclusion Criteria:

  • Any implanted electrical device(s) including deep brain stimulator, hearing or visual implants (i.e., cochlear implant, auditory brainstem implant, retinal prostheses), and/or cardiac defibrillator/pacemaker.
  • Implanted metallic device within 20 cm of the Treatment electrode (study eye(s)) and/or the grounding electrode (base of the hairline on the back of the neck).
  • Uncontrolled diabetes, defined as glycated haemoglobin (HbA1c) >10% (13.3 mmol/L).
  • Current tobacco or tobacco-related product use or history within the past 5 years of heavy smoking (defined as, on average, more than half a pack of cigarettes per day).
  • Known severe allergy to fluorescein dye.
  • Medical diagnosis of severe dry eye defined as requiring either artificial tears more than six (6) times a day or prescription drops (i.e., Restasis, Xiidra, or Cequa).
  • History of seizure disorders, chronic migraines and/or cluster headaches.
  • History and/or evidence of diabetic retinopathy in either eye as assessed by CF, fundus fluorescein angiography (FA), and OCT, to be confirmed by the Central Reading Centre.
  • Other conditions which pre-dispose to chorioretinal atrophy such as inherited retinal dystrophy (i.e., Stargardt's disease, Best's disease, pattern dystrophy, central areolar choroidal dystrophy, etc.).
  • History and/or evidence of exudative AMD in the study eye as assessed by CF, FA (or OCT-A ), and OCT, to be confirmed by Central Reading Centre.
  • GA involving the foveal centre, as assessed by the Central Reading Centre using AF and OCT.
  • History of intravitreal injections for GA (e.g., Syfovre or Izervay).
  • Treatment with photobiomodulation (PBM) therapy or short pulse laser within 12 months prior to screening.
  • Glaucoma requiring ≥3 medications and/or drops per day, or history of trabeculectomy.
  • History of any kind of intraocular surgery, excluding cataract surgery performed ≥3 months from Screening.
  • History of yttrium aluminium garnet (YAG) laser posterior capsulotomy \<1 month from Screening.
  • Visually significant cataracts and/or visually significant posterior capsular opacification.
  • History of amblyopia.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Active i-Lumen AMD therapy

    Active transpalpebral microcurrent therapy

    Device: i-Lumen AMD

  • Sham comparator
    Sham i-Lumen AMD therapy

    Sham transpalpebral microcurrent therapy

    Device: i-Lumen AMD

Interventions

  • Devicei-Lumen AMD

    i-Lumen AMD transpalpebral microcurrent stimulation system

06

What researchers measure

Primary outcomes

  1. Mean Change BCVA from Baseline

    Mean change in per-eye (treated study eye \[unilateral\] or treated primary study eye \[bilateral\]) from Baseline in distance BCVA letter score on the ETDRS VA chart, active vs sham.

    Time frame: Month 3

Secondary outcomes

  1. Portion of per-eye Responders

    1\. Difference in proportion of per-eye (treated study eye \[unilateral\] or treated primary study eye \[bilateral\]) gaining ≥10 letters from Baseline in distance BCVA ETDRS, active vs sham.

    Time frame: Month 3

  2. Mean Change BCVA from Baseline

    Mean change in per-eye (treated study eye \[unilateral\] or treated primary study eye \[bilateral\]) from Baseline in distance BCVA letter score on the ETDRS VA chart, active vs sham.

    Time frame: Month 6

07

Study locations

11 of 13 sites recruiting
  • Retina Consultants San Diego
    Poway, California 92064, United States
    • Research Coordinator · Contact · dcarbajal@rcsd.com · 858-451-1911
    • Nicholas London, MD · Principal investigator
    Recruiting
  • Retina Consultants PC
    Manchester, Connecticut 06042, United States
    • Chris Research Coordinator · Contact · cdwy@retinact.com · 860-646-7704 x113
    • Noam Rudnick, MD · Principal investigator
    Recruiting
  • University Retina & Macula Associates
    Lemont, Illinois 60439, United States
    Recruiting
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
    Not yet recruiting
  • Retina Associates of Cleveland
    Beachwood, Ohio 44122, United States
    Recruiting
  • Texas Retina Associates
    Fort Worth, Texas 76104, United States
    • Lori Research Coordinator · Contact · lmullen@texasretina.com · 817-334-0882 x411
    • Patrick Williams, MD · Principal investigator
    Recruiting
  • Tyler Retina Research Insitute
    Tyler, Texas 75703, United States
    • Melissa Long Research Coordinator · Contact · mlong@tylerretina.com · 903-597-4644
    • Samuel Minaker, MD · Principal investigator
    Recruiting
  • Cerulea
    East Melbourne, Victoria, Australia
    Active, not recruiting
  • Auckland Eye Limited
    Remuera, Auckland 1050, New Zealand
    • Alice Research Coordinator · Contact · Alice@aucklandeye.co.nz · 64 09 529 2480
    • Riyaz Bhikoo · Principal investigator
    Recruiting
  • Queens University Belfast / Belfast City Hospital
    Belfast, United Kingdom
    • Therese Research Coordinator · Contact · t.kearney@qub.ac.uk · +44 02895 040342
    • Tunde Peto · Principal investigator
    Recruiting
  • King's College Hospital
    London, SE5 9RS, United Kingdom
    • Nikki Research Coordinator · Contact · noimottimson@nhs.net · +44 203 299 7791
    • Timothy Jackson, PhD, FRCOphth · Principal investigator
    Recruiting
  • London North West University Healthcare
    Middlesex, HA1 3UJ, United Kingdom
    • Sandali Research Coordinator · Contact · snammuniarachchge@nhs.net · +44 (0) 208 453 2077
    • Christiana Dinah, BSc, MB BS, MRes, FRCOphth · Principal investigator
    Recruiting
  • Sunderland Eye Infirmary
    Sunderland, SR2 9HP, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06662162
Lead sponsor
i-Lumen Scientific AUS PTY LTD
Collaborators
i-Lumen Scientific, Inc.
Responsible party
Sponsor
First posted
Oct 28, 2024
Start date
May 7, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Aug 26, 2026

Study contacts

Meredith Mundy
Contact
mmundy@i-lumen.com
408-440-7049
Meredith Mundy
study director · i-Lumen Scientific, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion